Unprecedented Power Grab: One Man Runs CDC

(LibertySociety.com) – Trump’s health team just put one man in charge of both NIH and the CDC—an unprecedented power shift that will determine whether public health serves evidence and families, or bureaucracy and politics.

Story Snapshot

NIH Director Dr. Jay Bhattacharya was appointed acting CDC director in February 2026 while keeping his NIH post, creating a rare dual-leadership structure.
The move follows months of turmoil at CDC, including the firing of Senate-confirmed director Susan Monarez after a dispute over vaccine-policy process.
Former acting CDC chief Jim O’Neill approved major changes to routine vaccine recommendations; Bhattacharya inherits those decisions and the institutional fallout.
Bhattacharya has criticized COVID-era lockdowns and mandates but told senators measles outbreaks are best addressed by parents vaccinating children for measles.

Dual Leadership Raises Stakes for CDC’s Direction

Dr. Jay Bhattacharya, already serving as President Trump’s NIH director, was tapped in mid-February 2026 to also serve as acting director of the CDC. The appointment places one official over the nation’s premier biomedical research agency in Bethesda and its central public-health agency in Atlanta. Reporting to date describes the arrangement as temporary until a permanent CDC director is nominated and confirmed, but the practical effect is immediate: one decision-maker now bridges research funding and public-health guidance.

Bhattacharya enters the CDC role with a public record that conservatives will recognize from the COVID years. He gained prominence as a Stanford physician-economist and a co-author of the Great Barrington Declaration, a document that argued against broad lockdowns in favor of more limited restrictions. Critics in the research sources say “natural” herd immunity without vaccines was unethical or unrealistic, but those disputes underscore why his appointment signals a philosophical pivot from the mandate-heavy posture many Americans resented.

CDC Turbulence: Firings, Interim Chiefs, and Policy Whiplash

The Bhattacharya appointment follows a chaotic leadership chain that has left the CDC cycling through directors in under a year. After the White House withdrew its first choice, former Rep. Dave Weldon, the agency saw Susan Monarez confirmed by the Senate in July 2025 and fired about a month later by HHS Secretary Robert F. Kennedy Jr. According to testimony described in the coverage, Monarez refused requests to preapprove vaccine recommendation changes and said she resisted replacing evidence with ideology.

Jim O’Neill then ran CDC on an acting basis from August 2025 until February 2026. The research notes O’Neill is a science and tech investor who did not bring medical or research experience to the role, and it credits him with approving major shifts in routine vaccine recommendations. Those changes included removing meningitis, flu, hepatitis A, and rotavirus vaccines from the CDC’s list of routinely recommended shots. Bhattacharya’s first challenge is not abstract reform—it is restoring steady, credible operations after rapid, high-impact reversals.

What Bhattacharya Has Actually Said About Vaccines

The most concrete indicator in the reporting about what Bhattacharya “wants” from the CDC is what he told senators directly. In early February 2026 testimony, he said the measles epidemic is best solved by parents vaccinating their children for measles. The available sources also portray his views as more nuanced than pure vaccine skepticism: he has supported vaccination against major childhood diseases while remaining sharply critical of shutdowns and mask mandates that collided with liberty, work, schooling, and family life.

That distinction matters for readers trying to separate process reform from medical advice. The research indicates Secretary Kennedy’s team frames its actions as cutting bureaucratic bloat and conflicts of interest. Critics quoted in the sources counter that the “Medical Freedom” framing can create different conflicts by empowering a loosely regulated wellness industry. The public facts available so far do not spell out Bhattacharya’s detailed CDC agenda line-by-line, so any forecast beyond his testimony and prior public positions would be speculation.

Institutional Damage Claims Collide With Calls for Accountability

Several accounts describe a CDC that is struggling internally. The research notes mass layoffs and closures of departments that track infectious disease trends, support mental health, and manage tobacco and substance-use prevention. Former CDC Chief Medical Officer Dr. Debra Houry told the Senate she resigned because leaders were reduced to “rubber stamps” and alleged science was censored and politicized. Demetre Daskalakis, a former CDC immunization leader who resigned after Monarez’s firing, warned the agency “needs dedicated leadership,” not an add-on job.

At the same time, the record in the sources shows why the Trump administration’s base sees an opening for overdue reform: the CDC’s guidance during COVID and the broader public-health bureaucracy sparked deep distrust, especially when policy choices hit churches, schools, small businesses, and family life. Bhattacharya’s dual role could either streamline accountability or overload a single leader across two major agencies. What is clear is that the next round of CDC decisions will land in a country already divided—and eager for transparent, evidence-driven governance.